The Quantellect read.As of Nov 19, 2026, 4 active firms cover Assembly Biosciences Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $43.00 to $52.00, so the covering firms are broadly aligned. The average target of $47.50 sits 112% above the current $22.42. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -56% this year and 2% next, consensus EPS building from about $0.02 next quarter toward $-2.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$47.50
+111.9% upside
Average target across 4 active firms as of Nov 19, 2026 vs $22.42 current
Highest Target$52.00
Average Target$47.50
Lowest Target$43.00
Detailed analyst forecasts for ASMB
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate ASMB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ASMB EPS & revenue forecast
EPS · NEXT QUARTER
$0.02
Range $0.02 – $0.02 · 1 analysts · -104% YoY
Next period, 1 analysts expect Assembly Biosciences Inc to earn $0.02 a share (range $0.02 – $0.02), versus $-0.54 a year earlier. Full-year consensus is $-0.12, growing to $-2.57 the year after.
REVENUE · NEXT QUARTER
$17.1M
Range $17.1M – $17.1M · 1 analysts · -23% YoY
Revenue is expected to reach $17.1M (range $17.1M – $17.1M), -23.0% year-over-year. Full-year consensus is $71.4M, rising to $34.1M next year.
Top analysts covering Assembly Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ASMB.
#1
Ed Arce
HC Wainwright & Co. · Rank #168
Neutral
No targeton ASMB
Overall win rate
44%
+ Follow
#2
Roy Buchanan
JMP Securities · Rank #176
Buy
$38.00+69.5% to target
Overall win rate
47%
+ Follow
#3
Vamil Divan
Guggenheim · Rank #211
Buy
$43.00+91.8% to target
Overall win rate
48%
+ Follow
#4
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$50.00+123.0% to target
Overall win rate
36%
+ Follow
#5
Salim Syed
Mizuho
Buy
$45.00+100.7% to target
Coverage
—
+ Follow
ASMB stock forecast FAQ
What is ASMB's average 12-month price target?+
The 4 active firms with a live target average $47.50 for Assembly Biosciences Inc over the next 12 months, ranging from a $52.00 high to a $43.00 low, as of Nov 19, 2026.
Is ASMB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ASMB?+
The Street-high target is $52.00 (UBS), and the Street-low is $43.00 (Guggenheim). The average of all 4 active-firm targets is $47.50.
How many active Wall Street firms cover ASMB?+
4 active firms have a recognized rating on Assembly Biosciences Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ASMB?+
Among analysts who currently cover ASMB, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #168). Their current call is Neutral.
What is Assembly Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $0.02 per share (range $0.02 – $0.02) across 1 analysts. Full-year EPS is projected at $-0.12, rising to $-2.57 the following year.
How much revenue is Assembly Biosciences Inc expected to report next quarter?+
Consensus revenue is $17.1M (range $17.1M – $17.1M). Full-year revenue is projected at $71.4M, growing to $34.1M next year.
Have analysts been upgrading or downgrading ASMB lately?+
As of Nov 19, 2026, 4 of 4 active firms rate ASMB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ASMB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.